Lord’s Mark Industries Unlisted Share
About Lord’s Mark Industries Unlisted Share
Lords Mark Group, established in 1998 as a paper business, has evolved into a diversified conglomerate. Today, the group focuses on high-growth sectors—primarily In-Vitro Diagnostics (IVD), MedTech, and Renewable Energy.
With a strategic shift away from legacy businesses, Lords is actively divesting its paper division and planning a reverse merger to enter the listed space, signaling aggressive expansion and transformation.
Business Divisions
a) IVD / MedTech Division
Focused on rapid diagnostics and non-communicable disease management
Portfolio includes 34+ rapid test kits, surgical consumables, and biochemicals
Expanding into genome testing and B2C with E-smart clinics
b) Renewable Energy / LED Division
Market leader in rooftop solar installations in UP and Bihar
Strategic partnerships with Philips and defense projects
500 MW solar project target over 7 years; current order book: ₹2,000+ Cr
c) Paper Division (To Be Divested)
Currently contributes 18% of revenue
Planned divestment to focus on high-growth MedTech and solar verticals
Financial Highlights (FY22–FY24)
1. Revenue Growth:
Revenue surged from ₹213 Cr (FY22) to ₹555 Cr (FY24), indicating a CAGR of 28%.
2. Profitability Metrics:
EBITDA improved from ₹13.1 Cr to ₹38 Cr with a CAGR of 62%, while PAT rose from ₹4.2 Cr to ₹11.3 Cr (CAGR 93%).
3. Margin Expansion:
Gross margins increased from 8.92% to 13.33%, and OPM remained stable above 6%, reflecting operational efficiencies.
4. EPS Movement:
EPS stood at ₹1.01 in FY24, rising from ₹0.82 in FY23, despite equity dilution.
5. Strong Asset Base:
Total assets grew from ₹220 Cr to ₹357 Cr, with fixed assets rising from ₹18.8 Cr to ₹47 Cr.
6. Borrowings & Leverage:
Borrowings increased from ₹123 Cr (FY22) to ₹216 Cr (FY24), funding aggressive expansion.
7. Capital Structure:
Share capital expanded from ₹5 Cr to ₹56.2 Cr, while reserves reached ₹32.6 Cr, indicating equity infusions to support growth.
Pros
- High CAGR in PAT and EBITDA, reflecting strong profitability momentum
- Robust Order Book (₹2,000+ Cr) across solar and healthcare segments
- Strategic Industry Shift towards IVD/MedTech and Renewable Energy sectors
Cons
- Rising Finance Costs from ₹6 Cr to ₹18.2 Cr, impacting net margins
- High Debt Levels due to expansion-led borrowings
- Equity Dilution from ₹5 Cr to ₹56.2 Cr may affect existing shareholder value
Key Details
Key Details
| Share Name | Lord’s Mark Industries Unlisted |
|---|---|
| Shares Price | ₹120.00 Per Equity Share |
| Lot Size | 500 Shares |
| 52 Week High | ₹275 |
| 52 Week Low | ₹125 |
| Depository | NSDL & CDSL |
| PAN Number | AAACL9328F |
| ISIN Number | INE0MPL01010 |
| CIN | U21000MH1998PTC115601 |
| RTA | Link Intime |
| Fundamentals | Value |
|---|---|
| Market Cap (in cr.) | 678.99 |
| P/E Ratio | 118.81 |
| P/B Ratio | 14.32 |
| Debt to Equity | 3.52 |
| ROE (%) | 12.73 |
| Book Value | 8.38 |
| EPS | 1.01 |
| Face Value | 5 |
| Total Shares | 56,582,108.00 |
Financials
| P&L Statement | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 555 | 305 | 213 |
| Cost of Material Consumed | 481 | 270 | 194 |
| Gross Margins (%) | 13.33 | 11.48 | 8.92 |
| Change in Inventory | 0 | 0 | 0 |
| Employee Benefit Expenses | 17 | 6.6 | 1.8 |
| Other Expenses | 19 | 6.2 | 4.1 |
| EBITDA | 38 | 22.2 | 13.1 |
| OPM (%) | 6.85 | 7.28 | 6.15 |
| Other Income | 1.5 | 0.8 | 0.9 |
| Finance Cost | 18.2 | 11.5 | 6 |
| D&A | 5 | 4.6 | 2.1 |
| EBIT | 33 | 17.6 | 11 |
| EBIT Margins (%) | 5.95 | 5.77 | 5.16 |
| PBT | 15.5 | 6.4 | 5.5 |
| PBT Margins (%) | 2.79 | 2.10 | 2.58 |
| Tax | 4.2 | 1.8 | 1.3 |
| PAT | 11.3 | 4.6 | 4.2 |
| NPM (%) | 2.04 | 1.51 | 1.97 |
| EPS | 1.01 | 0.82 | 4.2 |
| Financial Ratios | FY23 | FY22 |
|---|---|---|
| Operating Margin | 6% | 5% |
| Net Profit Margin | 2% | 2% |
| Return on Equity | 12% | 13% |
| Debt-Equity | 3.52 | 1.89 |
| Current Ratio | 1.75 | 1.6 |
| Dividend Payout | 0% | 0% |
| Company | Lords Mark |
|---|---|
| Market Cap (₹ Crores) | 707 |
| Profitability Margin (%) | 2% |
| ROCE (%) | 16% |
| ROE (%) | 12% |
| D/E Ratio | 3.52 |
| P/E Ratio | 198.41 |
| P/B Ratio | 14.91 |
| Book Value per Share (₹) | 8.38 |
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Fixed Assets | 47 | 35 | 18.8 |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| Trade Receivables | 159 | 84.7 | 112 |
| Inventory | 99 | 91.4 | 67.8 |
| Other Assets | 52 | 29.4 | 21.6 |
| Total Assets | 357 | 240.5 | 220.2 |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share Capital | 56.2 | 28.2 | 5 |
| FV | 5 | 5 | 5 |
| Reserves | 32.6 | 18 | 27.6 |
| Borrowings | 216 | 175 | 123 |
| Trade Payables | 17.2 | 11.3 | 58.6 |
| Other Liabilities | 35 | 8 | 6 |
| Total Liabilities | 357 | 240.5 | 220.2 |
